Preventicus engineers products for smartphones and smartwatches that obtain health parameters without any extra accessories. The data generated are conclusive to a degree previously only obtainable by physicians. Another unique quality: All apps are medical devices with an accuracy verified in clinical studies.
Our special healthcare agreement ‘RhythmusLeben’ in collaboration with our partner GWQ ServicePlus AG is open to all statutory health insurance providers.
GWQ is a service provider founded by company health insurance funds, which currently represents 76 shareholder and customer insurance funds with around 13 million insured persons. They see themselves as a group of medium-sized health insurance companies, for which they develop solutions to improve the cost-effectiveness and quality of care. GWQ’s agreements and services can be used by all health insurance funds as shareholder or customer insurance funds.
Preventicus was one of the winners of the first Healthy Hub call, a market entry platform for the first healthcare market. This platform was created by five statutory health insurance funds who joined forces. Together with our HealthyHub partner IKK Südwest, we continuously test and improve our pilot project ‘RhythmusLeben’ in real market conditions.
The service division of the Bundesverbandes niedergelassener Kardiologen (German state association of licensed cardiologists) supports GWQ in the roll-out of the ‘RhythmusLeben’ programme. As a subsidiary of the Bundesverbandes niedergelassener Kardiologen (BNK) e.V., BNK Service GmbH represents more than 90% of all licensed cardiologists active in Germany. This gives them access to a unique network and offers extensive access to care for cardiovascular patients.
We work closely together with Getemed Medizin- und Informationstechnik AG and predominantly use Cardiomem XT devices for our atrial fibrillation diagnostics services. GETEMED has over 35 years of experience in developing, producing and marketing medical devices for functional cardiac diagnostics, ambulant monitoring of the vital signs of high-risk patients and telemonitoring. The company from Brandenburg, with headquarters in Teltow, has consistently and successfully expanded its position on the international market by focussing on these applications.
AFNET – The Atrial Fibrillation NETwork is the legal sponsor of the ‘Heart rhythm week Ulm’ study (October 2019), for which Preventicus is providing the technology and IT backbone. The Atrial Fibrillation NETwork is based on an interdisciplinary collaboration between doctors and scientists. Clinics and practices build a network – from GP to university medical centre.
Preventicus collaborates with the Global Clinical + Care Coordination Forum (GCCCF), which offers a comprehensive overview of the necessary transformation of care. Due to a change in demographics and increased patient requirements in combination with limited budgets for the healthcare and social sector, innovative solutions are required. Considering the enormous challenges we are facing with regard to the care continuum worldwide, it makes sense that sustainable solutions can only be developed through interdisciplinary collaboration of science, politics, economy and civil society.
Preventicus is supported by two of the European Union research projects (Horizon 2020: SME Instruments Phase II and Eurostars). Horizon 2020 is the European Union’s framework programme for research and innovation. The aim of this funding programme is to build an EU-wide association built on science and innovation and a competitive economy, and at the same time contribute to sustainable development.
The Horizon 2020 funding project (SME Instruments Phase II) ‘Redstroke’ (Reducing Stroke in Europe) in particular enables Europe-wide clinical studies based on Preventicus technology. This together with the programme’s aim to commercialise the Preventicus healthcare programme in other European countries, an aim which Horizon 2020 fully supports. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 829639
University of Basel, Switzerland
PD Dr med. Jens Eckstein
Study centre, PI, CRO
University of Athens, Greece
Prof. Athanasios Manolis
Greifswald University (Germany)
Prof. Dr med. Marcus Dörr
University of Belgrade (Serbia)
Dr Milica Vukicevic
Maastricht University, the Netherlands
Prof. Dr Ulrich Schotten
Stroke Alliance for Europa
University of Birmingham
(UK), PD Dr Larissa Fabritz, Prof. Dr Paulus Kirchhof
Deutsche Gesellschaft für Kardiologie (German Cardiac Society) / AG Rhythmologie
Prof. Dr Thomas Deneke
Jagiellonian University (Poland)
Prof. Dariusz Dudek
The guideline for Research, Technology and Innovation (FTI [Forschung, Technologie und Innovation] guideline) of the state of Thüringen especially promotes small and medium-sized companies to drive the transfer of research results into developments with a potential economic value.
“Development and provision of a scientifically validated, sustainable nutritional concept for the reduction of cardiovascular risk factors in the form of a digital mobile application (app)”.
Dr Christine Dawczynski and Prof. Stefan Lorkowski, Institute of Nutritional Sciences, Friedrich-Schiller University of Jena